Inhibition of COX-2 and EGFR by Melafolone Improves Anti-Pd-1 Therapy Through Vascular Normalization and PD-L1 Downregulation in Lung Cancer

Journal of Pharmacology and Experimental Therapeutics - United States
doi 10.1124/jpet.118.254359
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Society for Pharmacology & Experimental Therapeutics (ASPET)

Related search

Rationale of Combination of Anti-Pd-1/Pd-L1 Antibody Therapy and Radiotherapy for Cancer Treatment

International Journal of Clinical Oncology
MedicineSurgeryOncologyHematology
2020English

Aspirin‐targeted PD‐L1 in Lung Cancer Growth Inhibition

Thoracic Cancer
MedicinePulmonaryRespiratory MedicineOncology
2020English

Testing PD-1/PD-L1 Expression in Cancer Therapy: Pathologic Insights and Economic Sustainability

Archives of Pathology and Laboratory Medicine
MedicineForensic MedicinePathologyMedical Laboratory Technology
2016English

Oncolytic Virus and PD-1/PD-L1 Blockade Combination Therapy

Oncolytic Virotherapy
2018English

PD-1 and PD-L1 Expression in Molecularly Selected Non-Small-Cell Lung Cancer Patients

British Journal of Cancer
Cancer ResearchOncology
2014English

P3.01-18 Comparison of PD-L1 Immunohistochemical Assays and Clinical Response to Anti PD-1 Checkpoint Inhibitors in Patients With Lung Cancer

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Upregulation of PD-L1 Expression by Prostaglandin E2 and the Enhancement of IFN-γ by Anti-Pd-L1 Antibody Combined With a COX-2 Inhibitor in Mycoplasma Bovis Infection

Frontiers in Veterinary Science
Veterinary
2020English

PD-1/PD-L1 Blockade: A New Promising Therapy for the Treatment of Pancreatic Cancer?

Pancreas - Open Journal
2018English

PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer

Breast Care
SurgeryOncology
2016English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy